| Project/Area Number |
18K08987
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56010:Neurosurgery-related
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
Takano Shingo 筑波大学, 附属病院, 病院講師 (50292553)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
加藤 幸成 東北大学, 未来科学技術共同研究センター, 教授 (00571811)
山下 年晴 筑波大学, 医学医療系, 助教 (50400677)
|
|---|
| Project Period (FY) |
2018-04-01 – 2024-03-31
|
| Project Status |
Completed (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 血管新生抑制 / VEDGF抵抗性 / 血管co-option / 血管mimicry / chetomin / 膠芽腫 / VEGF / vascular mimicry / vascular co-option / bavacizumab / bevacizumab / 血管新生抑制療法 / 低酸素領域 / 血管新生抑制療 / glioblastoma / anti-angiogenesis / vasculogenic mimicry / angiogenesis / antiangiogenic therapy |
|---|
| Outline of Final Research Achievements |
Anti-angiogenic treatment fo glioblastome was not effective in clinical study, due to resistance suchi as vascular mimicry and vessel co-option. In this study, we developed in vitro VM and co-option model, and using this model, we found several target factors of VM and co-option. Inhibitors of SDF-1, connexin43 and chetomin inhibited GBM induced VM and co-option. Also these factors were strongly appeared in glioblastoma specimens. These inhibitors should be used for resistance case of angiosuppression of glioblastoma.
|
| Academic Significance and Societal Importance of the Research Achievements |
血管新生のvasculogenic mimcryとco-optionは膠芽腫血管新生抑制療法の抵抗性に関わる因子で、その標的分子を明らかにすることができた。標的は膠芽腫検体でも確かめられており、今後さらなる分子の開発が期待される。また、本研究で明らかにされたchetominの抵抗性の抑制作用は、HIF1抑制作用と合わせて実臨床での検討が期待れる。
|
